First Manhattan’s Vir Biotechnology VIR Stock Holding History

First Manhattan’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-192	Closed	-$1.94K	–	1303
2024 Q1	$1.94K	Buy	+192	New	+$1.96K	﹤0.01%	1284

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

First Manhattan's VIR Position: Q2 2024 in Review

First Manhattan sold out of Vir Biotechnology (VIR) in Q2 2024, closing a stake of 192 shares — an estimated $1.94K sold.

First Manhattan first reported a position in VIR in Q1 2024 and held it in 1 quarter. The position peaked at $1.94K in Q1 2024. 215 funds tracked by Wall St. Rank hold VIR as of Q2 2024.

First Manhattan reported no remaining Vir Biotechnology position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 192 Vir Biotechnology shares in Q2 2024, an estimated $1.94K.
First Manhattan first reported a position in Vir Biotechnology in Q1 2024 and held it in 1 quarter.
First Manhattan's Vir Biotechnology position peaked at $1.94K in Q1 2024.
215 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.